Preferred Label : hVEGF26-104/RFASE Peptide Vaccine;
NCIt synonyms : hVEGF26-104/RFASE;
NCIt definition : A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the
human angiogenic activator vascular endothelial growth factor (VEGF), consisting of
79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant
RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular
vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces
an immune response against VEGF, which results in anti-VEGF antibody binding to and
neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to
the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting
in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key
role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs
to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently
coupled to lipid groups and sulphate groups, and is able to induce a strong humoral
immune response upon antigen administration.;
Origin ID : C118364;
UMLS CUI : C3897146;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
